DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "Smart Insulin Pens Market by Type - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering. The global smart insulin pens market was valued at $57 million in 2016, and is estimated to reach $117 million by 2023, growing at a CAGR of 10.7% from 2017 to 2023. Smart insulin pen is a medical device used to inject insulin for the treatment of diabetes. Insulin pens have an attached insulin cartridge and hence do not need a syringe and separate vial. The market is expected to witness significant growth during the forecast period owing to rising geriatric population coupled with increasing incidence of diabetics. In addition, these pens can be easily used by people with visual or fine motor skills impairments further stimulates the market growth. However, insulin pens are inconvenient to use for the patients in need of mixture of two type of insulins, which in turn impedes the market growth. The global smart insulin pens market is segmented on the basis of type, usability, end user, and region. Based on type, the market is classified into first generation and second generation insulin pens. The second generation insulin pens are further bifurcated into Bluetooth-enabled and USB-connected insulin pens. By usability, it is segmented into pre-filled and reusable insulin pumps. According to the end user, the market is classified into hospitals & clinics, ambulatory surgical centers, and home care settings. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Complanies Mentioned:

Eli Lilly and Company Novo Nordisk Companion Medical DIAMESCO Emperra GmbH

Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Smart Insulin Pens Market, By Type Chapter 5 Smart Insulin Pens Market, By Usability Chapter 6 Smart Insulin Pens Market, By End-User Chapter 7 Smart Insulin Pens Market, By Region Chapter 8 Company Profiles For more information about this report visit https://www.researchandmarkets.com/research/j2fms6/global_smart?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005733/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Diabetes Devices

KEYWORD:

INDUSTRY KEYWORD: TECHNOLOGY HEALTH MEDICAL DEVICES PHARMACEUTICAL MOBILE/WIRELESS DIABETES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 06:34 AM/DISC: 06/12/2018 06:33 AM

http://www.businesswire.com/news/home/20180612005733/en